Scoop has an Ethical Paywall
Vertex Statement Regarding Trikafta
Vertex is extremely disappointed that Pharmac has decided not to prioritise funding of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for New Zealand’s cystic fibrosis (CF) patients.
We understand that Pharmac must make choices within a fixed budget, about which patient groups will have access to new, innovative medicines. However, we are surprised by this decision, particularly given their recent public acknowledgment of the clinical impact that Trikafta would have on CF patients in New Zealand.
Vertex remains committed to New Zealand’s CF community and will continue to work collaboratively with Pharmac to find a path forward so that those Kiwis who can benefit from Trikafta have the same access as patients in more than 30 other countries around the world.
NZEI Te Riu Roa: Mandated Single Approach To Reading Will Not Work
The Conversation: Could The School Phone Ban Work?
Public Health Communication Centre: To Avoid A Measles Epidemic, Aotearoa Must Close The ‘Immunity Gap’
Heritage New Zealand: Kid-friendly Archaeology Resource Kit Launched As Part Of Archaeology Week
Tatai Aho Rau Core Education: Cyber Skills Programme For Tamariki Recognised At Māori Language Awards
Waitaha Kapa Haka: Waitaha-South Island Kapa Haka Celebrates 60th Anniversary